Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia

Abstract

Background:The acute myeloid leukemia 1 (AML1)-eight-twenty-one (ETO) fusion protein generated by the t(8;21)(q22;q22) translocation is considered to display a crucial role in leukemogenesis in AML. By focusing on the anti-leukemia effects of eyes absent 4 (EYA4) gene on AML cells, we investigated the biologic and molecular mechanism associated with AML1-ETO expressed in t(8;21) AML.Methods:Qualitative polymerase chain reaction (PCR), quantitative reverse transcription PCR (RT-PCR), and Western blotting analysis were used to observe the mRNA and protein expression levels of EYA4 in cell lines. Different plasmids (including mutant plasmids) of dual luciferase reporter vector were built to study the binding status of AML1-ETO to the promoter region of EYA4. Chromatin immunoprecipitation assay was used to study the epigenetic silencing mechanism of EYA4. Bisulfite sequencing was applied to detect the methylation status in EYA4 promoter region. The influence of EYA4 gene in the cell proliferation, apoptosis, and cell clone-forming ability was detected by the technique of Cell Counting Kit-8, flow cytometry, and clonogenic assay.Results:EYA4 gene was hypermethylated in AML1-ETO+ patients and its expression was down-regulated by 6-fold in Kasumi-1 and SKNO-1 cells, compared to HL-60 and SKNO-1-siA/E cells, respectively. We demonstrated that AML1-ETO triggered the epigenetic silencing of EYA4 gene by binding at AML1-binding sites and recruiting histone deacetylase 1 and DNA methyltransferases. Enhanced EYA4 expression levels inhibited cellular proliferation and suppressed cell colony formation in AML1-ETO+ cell lines. We also found EYA4 transfection increased apoptosis of Kasumi-1 and SKNO-1 cells by 1.6-fold and 1.4-fold compared to negative control, respectively.Conclusions:Our study identified EYA4 gene as targets for AML1-ETO and indicated it as a novel tumor suppressor gene. In addition, we provided evidence that EYA4 gene might be a novel therapeutic target and a potential candidate for treating AML1-ETO+ t (8;21) AML.

Limited Role of Promoter Methylation of MGMT and C13ORF18 in Triage of Low-Grade Squamous Intraepithelial Lesion

“…On the contrary, there may be gene silence first, and promoter methylation acts as epigenetic marks. [ 14 15 ]…”

Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia

“…Intriguingly, without any microscopically detectable chromosome abnormalities in its leukemic blast, CN-AML harbour aberrantly expressed genes and microRNAs, mutations, epigenetic changes that can be used as potential prognostic markers (8). It is now recognized that WT1, ASXL1, DNMT3A, FLT3-ITD and TET2 mutations presence in CN-AML represent a subgroup of patients with unfavorable prognosis, while NPM1 and CEBPA are associated with favorable prognosis (9)(10)(11)(12)(13)(14)(15). Furthermore, unfavorable prognostic factors include high expression of CPT1A, ATP1B1, RUNX1, MAPKBP1, MAP7, ERG, DNMT3B, miR-3151, miR-155, etc.…”

EYA4 could be an indicator signifying colorectal cancer sufferers' prognoses

“…EYA4, a member of EYA family, has recently been identi ed as a tumor suppressor gene in many kinds of cancers, including hepatocellular carcinoma, acute myeloid leukemia, oral cancer, etc [14,24,25]. In the current study, we investigated the functional roles of EYA4 in CRC.…”